Haisco Pharmaceutical Group Co., Ltd.

This study tests an experimental oral drug, HSK39297, in people with lupus nephritis – a serious kidney complication of lupus. About 105 adults will receive either 200 mg, 300 mg, or a placebo daily for several weeks. The main goal is to see if the drug reduces protein in the uri…

This early-phase study tests an experimental oral drug, HSK42360-Na, in adults with advanced solid tumors that have a specific genetic change (BRAF V600 mutation) and have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and…

This study tests an experimental drug called HSK42360 in children aged 6 to 17 with a type of brain tumor that has a specific genetic change (BRAF V600 mutation) and has come back after standard treatment. The main goals are to find the safest dose and to see if the drug can shri…

This early-phase study tests an experimental tablet (HSK47977) in 110 adults whose Non-Hodgkin's lymphoma has returned or stopped responding to treatment. The main goals are to find the safest dose and check for side effects, while also looking at how well the drug works. Partici…

This study tests a new tablet called HSK39297 for people with IgA Nephropathy, a kidney disease. The goal is to see if it can lower protein in the urine and help protect kidney function over time. About 370 adults will take either the drug or a placebo for up to 104 weeks to chec…

This study tests a new medicine called HSK47388 for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 150 adults who haven't gotten better with other treatments will receive either the drug or a placebo. The goal…

This study tests a new pain medicine called HSK21542 for people who have hip replacement surgery. About 405 adults will receive either the new drug, morphine, or a placebo to see how well it controls pain and reduces side effects like nausea and vomiting. The goal is to find a sa…

This early-stage study tests the safety and tolerability of a new drug called HSK55879 in 46 healthy adults aged 18 to 45. Participants will receive either the drug or a placebo, and researchers will monitor side effects and how food affects the drug. The goal is to gather initia…

This study looks at how the body processes a new drug called HSK39297 for paroxysmal nocturnal hemoglobinuria (PNH) in people with mild or moderate liver problems compared to those with healthy livers. About 24 adults will receive a single dose to measure drug levels and safety. …